New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development And Manufacturing Facilities From Talaris Therapeutics; No Financial Terms Disclosed
Portfolio Pulse from Benzinga Newsdesk
New York Blood Center Enterprises (NYBCe) has acquired commercial-scale cell and gene therapy development and manufacturing facilities from Talaris Therapeutics, Inc. (NASDAQ:TALS). The acquisition includes facilities in Houston, Texas and Louisville, Kentucky, as well as certain technologies and equipment. The deal will enhance NYBCe's cell and gene therapy development and manufacturing capabilities, and accelerate the delivery of a fully integrated vein-to-vein cell and gene therapy solution for the US.
October 04, 2023 | 12:39 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Talaris Therapeutics has sold its cell and gene therapy development and manufacturing facilities to NYBCe. The deal could potentially impact Talaris' operational capabilities and financial position, although the financial terms were not disclosed.
The sale of these facilities could have a significant impact on Talaris' operations, as it may affect the company's ability to develop and manufacture its own therapies. However, without financial details, it's difficult to assess the exact impact on the company's financial position. The news is highly relevant as it directly involves Talaris, and it's important for investors to understand how this could affect the company's future operations and financial health.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100